ACRV
NASDAQAcrivon Therapeutics Inc.
News25/Ratings11
News · 26 weeks68+450%
2026-03-012026-08-23
Mix2190d
- Insider14(67%)
- SEC Filings4(19%)
- Other3(14%)
Latest news
25 items- INSIDERChief Legal Officer Miller Mary sold $372 worth of shares (185 units at $2.01), decreasing direct ownership by 0.23% to 82,009 units (SEC Form 4) (withholding tax)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERChief Accounting Officer Peterson Katharine sold $203 worth of shares (101 units at $2.01), decreasing direct ownership by 0.56% to 18,033 units (SEC Form 4) (tax liability)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERChief Development Officer Gamelin Erick sold $804 worth of shares (400 units at $2.01), decreasing direct ownership by 0.75% to 52,592 units (SEC Form 4) (for tax liability)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERChief Operating Officer Devroe Eric sold $1,214 worth of shares (604 units at $2.01), decreasing direct ownership by 0.41% to 146,349 units (SEC Form 4) (for tax liability)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERPresident and CEO Blume-Jensen Peter sold $3,443 worth of shares (1,713 units at $2.01) (SEC Form 4) (tax liability)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- SECSEC Form S-8 filed by Acrivon Therapeutics Inc.S-8 - Acrivon Therapeutics, Inc. (0001781174) (Filer)
- SECAcrivon Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
- SECSEC Form 10-Q filed by Acrivon Therapeutics Inc.10-Q - Acrivon Therapeutics, Inc. (0001781174) (Filer)
- PRAcrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data CatalystsACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026 ACR-2316 Phase 1/2 trial in AP3-prioritized tumor types advancing in randomized dose expansion phase supported by a promising, favorable safety profile and durable single-agent clinical activity in several tumor types Cash, cash equivalents, and marketable securities of $90.0 million as of June 30, 2026 expected to fund operations into fourth quarter of 2027 WATERTOWN, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering
- INSIDERChief Financial Officer Levy Adam D. sold $1,793 worth of shares (1,142 units at $1.57), decreasing direct ownership by 2% to 66,008 units (SEC Form 4) to satisfy withholding tax4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- PRAcrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 StudyFavorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a year Oral weekly regimen (3 days on/4 days off) at 120 mg and 160 mg QD dose levels selected for randomized dose optimization across AP3-informed solid tumor populations Dose expansion to evaluate biomarker-selected small cell lung cancer (SCLC), squamous non-small cell lung cancer (sqNSCLC), lung adenocarcinoma (adNSCLC), as well as endometrial, cervical, and esophago-gastric junction cancers WATERTOWN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NAS
- INSIDERChief Legal Officer Miller Mary sold $1,008 worth of shares (573 units at $1.76), decreasing direct ownership by 0.69% to 82,194 units (SEC Form 4) (for withholding tax)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- PRAcrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 ConferencePresentations feature mechanistic data on ACR-2316, a potential first-in-class, clinical WEE1/PKMYT1 inhibitor, rationally designed with AP3 for potent single agent activity and superior therapeutic index Early clinical responses, including partial responses (PRs) across multiple AP3-predicted tumor types, underscore how AP3-guided drug design translates into differentiated anti-tumor activity WATERTOWN, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Pr
- INSIDERSEC Form 4 filed by Director Ra Capital Management, L.P.4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERSEC Form 4 filed by Director Tomsicek Michael John4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERSEC Form 4 filed by Director Shacham Sharon4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERSEC Form 4 filed by Director Palani Santhosh4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERSEC Form 4 filed by Director Magovcevic-Liebisch Ivana4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERSEC Form 4 filed by Director Dirocco Derek4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERSEC Form 4 filed by Director Baum Charles M4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- SECAcrivon Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
- INSIDERPresident and CEO Blume-Jensen Peter covered exercise/tax liability with 13,729 shares (SEC Form 4) to satisfy tax liability4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- SECSEC Form DEFA14A filed by Acrivon Therapeutics Inc.DEFA14A - Acrivon Therapeutics, Inc. (0001781174) (Filer)
- PRAcrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation SummitWATERTOWN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a virtual fireside chat on Tuesday, May 26, 2026, at 9:00 a.m. ET at TD Cowen's 7th Annual Oncology Innovation Summit. The live and archived webcast of this event can be accesse
- INSIDERDirector Ra Capital Management, L.P. was granted 9,366 shares (SEC Form 4)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
ACRV FAQ
6 questionsWhere does ACRV stock trade?
Acrivon Therapeutics Inc. (ACRV) is listed on NASDAQ.What sector and industry is ACRV in?
Acrivon Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Acrivon Therapeutics Inc. go public?
Acrivon Therapeutics Inc. (ACRV) completed its IPO in 2022.What are analysts saying about ACRV?
Acrivon Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight with a $600.00 price target on 2025-05-05. Recent price targets range from $600.00 to $2500.00.What companies are similar to ACRV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ACRV side-by-side with any of them on Quantisnow.How can I track ACRV on Quantisnow?
Quantisnow aggregates Acrivon Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACRV to receive live email and push alerts on every new disclosure.